Aldo-keto Reductase Family 1 B10 as a Novel Target for Breast Cancer Treatment
Annual rept. 1 Aug 2009-31 Jul 2010
SOUTHERN ILLINOIS UNIV SCHOOL OF MEDICINE SPRINGFIELD
Pagination or Media Count:
Breast cancer is the most common carcinoma of women in the United States, accounting for more than 40,000 American womens deaths annually. Targeted therapies, such as tamoxifen in estrogen receptor-positive breast cancer, have led to major important improvements in the outcomes of this cancer, but effective chemotherapy targets are lacking and the mortality rate of advanced breast cancer is still high. Aldo-keto reductase 1 B10 AKR1B10 is overexpressed in tested human breast cancer tissues and mediates acetyl-CoA carboxylase-alpha ACCA stability, affecting fatty acid de novo synthesis and cell growth. This study is aimed to identify and evaluate AKR1B10 as a now target for the treatment of breast cancer. In this study, we will determine AKR1B10 expression in breast cancer, define the role of AKR1B10 in lipid metabolism, proliferation, and tumorigenicity of breast cancer cells using AKR1B10-targeted breast cancer cells and animal tumor models, and elucidate the regulatory mechanisms of AKR1B10 on lipid metabolism of breast cancer cells via identifying the functional domains.
- Medicine and Medical Research